A discussion of the Mayo Collaborative Services v. Prometheus Laboratories, Inc. litigation where Prometheus sued Mayo for infringing certain claims of two patents covering a method of optimizing the therapeutic efficacy of treating a patient suffering from certain autoimmune diseases. The main issue is whether a method that uses certain individualized drug metabolite measurements based on a law of nature to inform the calibration of the patient's drug dosage is patent-eligible subject matter.